GeneDx Holdings Balance Sheet Health
Financial Health criteria checks 5/6
GeneDx Holdings has a total shareholder equity of $277.1M and total debt of $51.7M, which brings its debt-to-equity ratio to 18.6%. Its total assets and total liabilities are $463.9M and $186.7M respectively. GeneDx Holdings's EBIT is $7.1M making its interest coverage ratio 2.4. It has cash and short-term investments of $134.6M.
Key information
18.65%
Debt to equity ratio
US$51.68m
Debt
| Interest coverage ratio | 2.4x |
| Cash | US$134.56m |
| Equity | US$277.13m |
| Total liabilities | US$186.73m |
| Total assets | US$463.86m |
Recent financial health updates
Health Check: How Prudently Does GeneDx Holdings (NASDAQ:WGS) Use Debt?
Jun 24
Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Mar 17Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Dec 16Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29Recent updates
News Flash: Analysts Just Made A Captivating Upgrade To Their GeneDx Holdings Corp. (NASDAQ:WGS) Forecasts
Aug 07GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth
Jul 31Why Investors Shouldn't Be Surprised By GeneDx Holdings Corp.'s (NASDAQ:WGS) 28% Share Price Surge
Jun 27Health Check: How Prudently Does GeneDx Holdings (NASDAQ:WGS) Use Debt?
Jun 24With A 26% Price Drop For GeneDx Holdings Corp. (NASDAQ:WGS) You'll Still Get What You Pay For
May 02GeneDx: Strengthening Leadership In Genomic Diagnostics
Apr 28
Expanding Exome And Genome Testing Will Unlock Future Potential
GeneDx's focus on expanding genetic testing access and launching user-friendly products aims to significantly enhance revenue growth and market adoption.Is GeneDx Holdings Corp. (NASDAQ:WGS) Trading At A 31% Discount?
Apr 14Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Mar 17GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich
Mar 12Why Investors Shouldn't Be Surprised By GeneDx Holdings Corp.'s (NASDAQ:WGS) 32% Share Price Surge
Feb 27GeneDX Holdings Q4 2024 Earnings Preview
Feb 07GeneDx Holdings: A Phenomenal Comeback With More Room To Run
Jan 16GeneDx Holdings Corp. (NASDAQ:WGS) Looks Just Right With A 26% Price Jump
Jan 08Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Dec 16GeneDx: Possibly Turning A Profit In 2025 (Rating Downgrade)
Dec 16GeneDx Rides Revenue Surge, But Valuation Risks Loom
Dec 09GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce
Nov 23US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results
Nov 01GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
Oct 30GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
Oct 21After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar
Oct 04Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
Aug 19Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher
Jul 27GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors
Jun 12GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
Jun 06Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24Financial Position Analysis
Short Term Liabilities: WGS's short term assets ($204.8M) exceed its short term liabilities ($71.4M).
Long Term Liabilities: WGS's short term assets ($204.8M) exceed its long term liabilities ($115.3M).
Debt to Equity History and Analysis
Debt Level: WGS has more cash than its total debt.
Reducing Debt: WGS's debt to equity ratio has reduced from 19.2% to 18.6% over the past 5 years.
Debt Coverage: WGS's debt is well covered by operating cash flow (25.2%).
Interest Coverage: WGS's interest payments on its debt are not well covered by EBIT (2.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/05 18:06 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeneDx Holdings Corp. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Keith Hinton | Freedom Capital Markets |